You are here:
Home / Investors / Events & Presentations

Tools

Events & Presentations

Corporate Presentation
Date Documents
June 2, 2021
Corporate Presentation

Upcoming Events

There are currently no events to display.

Archived Investor Events and Presentations

Archived Scientific Presentations

Date Documents
April 10, 2021
IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents
April 10, 2021
PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
April 10, 2021
Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells
April 10, 2021
Affinity tuned XmAb® 2+1 GPC3 x CD3 bispecific antibodies demonstrate selective activity in liver cancer models
December 6, 2020
Complete Responses in Relapsed/ Refractory AML Patients on a Weekly Dosing Schedule of Vibecotamab, a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Results of a Phase 1 Study
November 9, 2020
Preliminary Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of XmAb®20717, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
November 9, 2020
Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
November 9, 2020
PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors
November 9, 2020
Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents
October 2, 2020
NANETS 2020: Preliminary Safety, PK/PD, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Patients With Advanced Neuroendocrine Tumors
June 22, 2020
AACR 2020: XmAb30819, an XmAb® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies
June 22, 2020
AACR 2020: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models
June 22, 2020
AACR 2020: Potency-reduced IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity
June 22, 2020
AACR 2020: Affinity tuned XmAb® 2+1 anti-mesothelin x anti-CD3 bispecific antibody induces selective T cell-dependent cellular cytotoxicity of human ovarian cancer cells
December 9, 2019
ASH 2019: Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with R/R NHL and CLL
March 4, 2019
Festival of Biologics USA 2019: Tumor selective cytotoxicity by TAA x CD3 bispecifics utilizing a 2:1 mixed-valency format
December 3, 2018
ASH 2018: Complete Responses in r/r AML Patients on a Weekly Dosing Schedule of XmAb®14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
December 3, 2018
ASH 2018: Regulatory T cell selective IL-2-Fc fusion proteins for the treatment of autoimmune diseases
November 9, 2018
SITC 2018: An IL15/IL15Rα heterodimeric Fc-fusion engineered for reduced potency demonstrates an optimal balance of in vivo activity and exposure
November 9, 2018
SITC 2018: Simultaneous checkpoint-costimulatory or checkpoint-checkpoint receptor targeting with bispecific antibodies promotes enhanced human T cell activation
October 21, 2018
ACR 2018: Top-line Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
April 18, 2018
AACR 2018: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure
April 16, 2018
AACR 2018: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation
November 13, 2017
SITC 2017: Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T CellActivation and Proliferation
November 13, 2017
SITC 2017: Anti-PD1 x anti-ICOS bispecific antibody XmAb23104 brings together PD1 blockade and ICOS costimulation to promote human T cell activation and proliferation
November 8, 2017
ACR 2017: Final Results from Phase 2 Study of XmAb 5871 in IgG4-Related Disease
June 16, 2017
EULAR 2017: Interim Results of a Phase 2 Study of XmAb®5871, a Reversible B Cell Inhibitor, in IgG4-Related Disease
April 4, 2017
AACR 2017: IL 15/IL 15Ra; heterodimeric Fc-fusions with extended half-lives
April 4, 2017
AACR 2017: Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation
April 4, 2017
AACR 2017: Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors
November 13, 2016
Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease
November 9, 2016
2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Dual Blockade of PD-1 and CTLA-4 with Bispecific Antibodies Promotes Human T cell Activation and Proliferation
November 9, 2016
2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Multiple Bispecific Checkpoint Combinations Promote T cell activation
June 12, 2015
European League Against Rheumatism (EULAR) 2015 Annual Meeting Poster: A Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis
December 7, 2014
American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD20 × Anti-CD3 Bispecific Antibodies in B-cell Lymphomas and Leukemia Chu, et al, Abstract ID# 3111
December 7, 2014
Xencor American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD123 x Anti-CD3 Bispecific Antibodies in Acute Myleogenous Leukemia Chu, et al, Abstract ID# 2316